LaNova Medicines employs a range of advanced technologies to develop innovative biologic drugs aimed at transforming cancer treatment. Central to their approach are three proprietary platforms: LX-TAb™, LX-ADC™, and LX-TDuo™. The LX-TAb™ platform focuses on targeted antibody discovery, particularly for multi-transmembrane proteins, enhancing screening efficiency and druggability. This platform has enabled the development of numerous novel antibodies that target tumor-associated antigens (TAAs) and immuno-oncology (IO) targets. The LX-ADC™ platform specializes in next-generation antibody-drug conjugates (ADCs), allowing for the creation of customized ADCs with improved efficacy and safety profiles. Notably, LM-302, an anti-Claudin18.2 ADC, is highlighted as a leading candidate in their pipeline, currently undergoing clinical trials.

Additionally, the LX-TDuo™ platform is designed to generate bispecific antibodies that engage immune cells specifically within the tumor microenvironment. This technology aims to activate immune responses against cancer cells while minimizing off-target effects, thus enhancing therapeutic potential. By leveraging these platforms, LaNova Medicines is committed to addressing the complexities of cancer treatment, focusing on the tumor microenvironment and developing a diverse pipeline of therapeutics that target various malignancies. Their innovative strategies reflect a deep understanding of tumor biology and a dedication to improving patient outcomes in oncology.

China

Founded in 2019 in Shanghai, China, LaNova Medicines is a clinical-stage biotechnology company committed to the discovery and development of novel biologic drugs for cancer treatment.

Led by industry veterans with a strong passion for innovation, we aim to operate as an R&D engine and deliver transformative medicines to address the unmet clinical needs of cancer patients. Leveraging our proprietary technology platforms and deep understanding of the tumor microenvironment. we have built a differentiated pipeline of products and are striving to progress our programs toward the clinic. 

LaNova Medicines

Company Details